Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of Nirmatrelvir/Ritonavir in Healthy Lactating Women
NCT05441215Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Nirmatrelvir and ritonavir in coronavirus disease 2019 (COVID-19), sponsored by Pfizer. Primary endpoints: Maximum Observed Concentration in Breast Milk, Time to Reach Cmax in Breast Milk and 2 more. Started Dec 2022; status: completed.
02
Drugs
Nirmatrelvirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05441215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05441215.